It seems there’s room for two in the MASH market. When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat the fatty liver disease, some investors thought it would put ...

Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to Endpoints News.

𝕏 Post on X in Share on LinkedIn ✉ Email a friend

Heard via Storyflo

Get audio versions of every article you read.

Pick what matters — your audio curator gets you into your daily flo.

Join the listener waitlist

Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape · Storyflo